Back to Newsroom
Back to Newsroom

APYX, APPS & VRCA Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors of Upcoming Deadlines and to Actively Participate

Tuesday, August 2, 2022 11:00 AM
Bronstein, Gewirtz and Grossman, LLC
https://www.bgandg.com/
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 2, 2022 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Bronstein, Gewirtz and Grossman, LLC, Tuesday, August 2, 2022, Press release picture

Apyx Medical Corporation (NASDAQ:APYX)
Class Period: May 12, 2021 - March 11, 2022
Deadline: August 5, 2022
For more info: www.bgandg.com/apyx.

That Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) a significant number of Apyx's Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company's financial results would be adversely impacted; and (5) consequently, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Digital Turbine, Inc. (NASDAQ:APPS)
Class Period: August 9, 2021 - May 17, 2022
Deadline: August 5, 2022
For more info: www.bgandg.com/apps1.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company's recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) that, as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) that the Company's internal control over financial reporting as to revenue recognition was deficient; and (4) that, as a result of the foregoing, the Company's net revenues was overstated throughout fiscal 2022; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)
Class Period: May 28, 2021 - May 24, 2022
Deadline: August 5, 2022
For more info: www.bgandg.com/vrca.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there were manufacturing deficiencies at the facility where the Company's contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when the Company resubmitted its NDA for VP-12 for molluscum; (3) that the foregoing presented significant risks to the Company obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Topic:
Lawsuits
Back to newsroom
Back to Newsroom